Search results
Featured news and updates for animal health professionals and users of veterinary medicines such as pet owners.
The European Medicines Agency (EMA) facilitates development and access to medicines for countries within the European Union (EU). EMA evaluates applications for marketing authorisation submitted via the centralised procedure, monitors the safety of medicines across their lifecycle and provides information to healthcare professionals and patients.
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). It is responsible for the scientific evaluation, supervision and safety monitoring of medicines.
The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).
The European Medicines Agency (EMA) protects and promotes human and animal health by evaluating and monitoring medicines within the European Union (EU) and the European Economic Area (EEA).
Oct 28, 2021 · Parliament and Council reached a provisional agreement on Thursday to make the European Medicines Agency more effective in tackling shortages of medicines and medical devices.
Jan 20, 2022 · The European Medicines Agency (EMA) will be better equipped to monitor and mitigate shortages of medicinal products and medical devices considered to be critical in order to address public health emergencies.
Jan 13, 2021 · Few medicines are awaited as eagerly as COVID-19 vaccines. Extraordinary efforts by scientists, regulators, and developers enabled the European Medicines Agency (EMA) to recommend the first EU conditional marketing authorisation (CMA) for the BioNTech COVID-19 mRNA vaccine (nucleoside-modified) BNT162b2 (Comirnaty)
Mar 1, 2022 · Details. Publication date. 1 March 2022. Author. Directorate-General for Health and Food Safety.
Jul 15, 2024 · The IMI AMYPAD project robustly assessed a numerical scale from 0-100 that can be used to quantitatively compare brain scans of Alzheimer’s patients. The method received a biomarker qualification opinion from the European Medicines Agency (EMA).
